Literature DB >> 25514762

Depressive symptoms and risk of uterine leiomyomata.

Lauren A Wise1, Se Li2, Julie R Palmer2, Lynn Rosenberg2.   

Abstract

OBJECTIVE: Uterine leiomyomata (UL) are a major source of gynecologic morbidity and the primary indication for hysterectomy. Depression can cause dysregulation of the hypothalamic-pituitary-adrenal axis, which may affect the synthesis of reproductive hormones involved in UL pathogenesis. We assessed the association between depressive symptoms and UL among 15,963 premenopausal women. STUDY
DESIGN: Data were derived from the Black Women's Health Study, a prospective cohort study. In 1999 and 2005, the Center for Epidemiologic Studies Depression Scale (CES-D) was used to ascertain depressive symptoms. On biennial follow-up questionnaires from 1999 through 2011, women reported physician-diagnosed depression, antidepressant use, and UL diagnoses. Incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were estimated using multivariable Cox regression.
RESULTS: There were 4722 incident UL cases diagnosed by ultrasound (n=3793) or surgery (n=929) during 131,262 person-years of follow-up. Relative to baseline CES-D scores<16, IRRs were 1.05 (95% CI, 0.98-1.13) for CES-D scores 16-24 and 1.16 (95% CI, 1.06-1.27) for CES-D scores≥25 (P-trend=.001). IRRs for current and past physician-diagnosed depression relative to no depression were 1.15 (95% CI, 0.98-1.34) and 1.25 (95% CI, 1.13-1.39), respectively. Results persisted after further control for antidepressant use. IRRs for current and past use of antidepressants (any indication) relative to never use were 1.11 (95% CI, 0.97-1.28) and 1.32 (95% CI, 1.14-1.52), respectively.
CONCLUSION: In this cohort of black women, greater depressive symptoms were associated with UL, independent of antidepressant use, supporting the hypothesis that dysregulation of the hypothalamic-pituitary-adrenal axis increases UL risk.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  African Americans; antidepressants; depressive symptoms; prospective studies; uterine neoplasms

Mesh:

Substances:

Year:  2014        PMID: 25514762      PMCID: PMC4417041          DOI: 10.1016/j.ajog.2014.12.012

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  62 in total

1.  Factorial invariance of the CES-D in low socioeconomic status African Americans compared with a nationally representative sample.

Authors:  Ha T Nguyen; Melissa Kitner-Triolo; Michele K Evans; Alan B Zonderman
Journal:  Psychiatry Res       Date:  2004-04-30       Impact factor: 3.222

2.  Urinary free cortisol excretion in depression.

Authors:  B J Carroll; G C Curtis; B M Davies; J Mendels; A A Sugerman
Journal:  Psychol Med       Date:  1976-02       Impact factor: 7.723

3.  The prevalence of major depression in black and white adults in five United States communities.

Authors:  P D Somervell; P J Leaf; M M Weissman; D G Blazer; M L Bruce
Journal:  Am J Epidemiol       Date:  1989-10       Impact factor: 4.897

4.  Brain hypoactivation, autonomic nervous system dysregulation, and gonadal hormones in depression: a preliminary study.

Authors:  Laura M Holsen; Jong-Hwan Lee; Sarah B Spaeth; Lauren A Ogden; Anne Klibanski; Susan Whitfield-Gabrieli; Richard P Sloan; Jill M Goldstein
Journal:  Neurosci Lett       Date:  2012-02-25       Impact factor: 3.046

5.  Reliability of the CES-D Scale in different ethnic contexts.

Authors:  R E Roberts
Journal:  Psychiatry Res       Date:  1980-05       Impact factor: 3.222

6.  Cerebrospinal fluid and plasma free cortisol concentrations in depression.

Authors:  B J Carroll; G C Curtis; J Mendels
Journal:  Psychol Med       Date:  1976-05       Impact factor: 7.723

7.  Inpatient hospitalization for gynecologic disorders in the United States.

Authors:  Maura K Whiteman; Elena Kuklina; Denise J Jamieson; Susan D Hillis; Polly A Marchbanks
Journal:  Am J Obstet Gynecol       Date:  2010-02-04       Impact factor: 8.661

8.  Depressive symptoms in relation to physical health and functioning in the elderly.

Authors:  L F Berkman; C S Berkman; S Kasl; D H Freeman; L Leo; A M Ostfeld; J Cornoni-Huntley; J A Brody
Journal:  Am J Epidemiol       Date:  1986-09       Impact factor: 4.897

9.  Presence and persistence of depressive symptoms in patient and community populations.

Authors:  T J Craig; P A Van Natta
Journal:  Am J Psychiatry       Date:  1976-12       Impact factor: 18.112

10.  Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study.

Authors:  Lauren A Wise; Julie R Palmer; Bernard L Harlow; Donna Spiegelman; Elizabeth A Stewart; Lucile L Adams-Campbell; Lynn Rosenberg
Journal:  Hum Reprod       Date:  2004-06-24       Impact factor: 6.918

View more
  3 in total

1.  Anxiety, Depression, and Quality of Life After Procedural Intervention for Uterine Fibroids.

Authors:  Kedra Wallace; Elizabeth A Stewart; Lauren A Wise; Wanda Kay Nicholson; John Preston Parry; Shuaiqi Zhang; Shannon Laughlin-Tommaso; Vanessa Jacoby; Raymond M Anchan; Michael P Diamond; Sateria Venable; Amber Shiflett; Ganesa R Wegienka; George Larry Maxwell; Daniel Wojdyla; Evan R Myers; Erica Marsh
Journal:  J Womens Health (Larchmt)       Date:  2021-06-08       Impact factor: 2.681

2.  Stress and spirituality in relation to HPA axis gene methylation among US Black women: results from the Black Women's Health Study and the Study on Stress, Spirituality and Health.

Authors:  Alexandra E Shields; Yuankai Zhang; M Austin Argentieri; Erica T Warner; Yvette C Cozier; Chunyu Liu; Christian K Dye; Blake Victor Kent; Andrea A Baccarelli; Julie R Palmer
Journal:  Epigenomics       Date:  2021-11-02       Impact factor: 4.778

3.  Uterine fibroids and incidence of depression, anxiety and self-directed violence: a cohort study.

Authors:  Stephanie E Chiuve; Carrie Huisingh; Natalia Petruski-Ivleva; Charlotte Owens; Wendy Kuohung; Lauren A Wise
Journal:  J Epidemiol Community Health       Date:  2021-07-22       Impact factor: 3.710

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.